CD25 Antibody / IL2RA, 100ug

IL2RA antibody targets Interleukin-2 receptor subunit alpha, a cell surface cytokine receptor component encoded by the IL2RA gene. Interleukin-2 receptor subunit alpha is also widely known as CD25 and represents the high-affinity binding subunit of the interleukin-2 receptor complex. This protein is primarily localized to the plasma membrane and is expressed at low levels on resting T cells but is rapidly upregulated following immune activation. Because of its central role in IL-2 signaling, an IL2RA antibody is extensively used in immunology research focused on T cell activation and immune regulation.<br><br>Interleukin-2 receptor subunit alpha forms a heterotrimeric receptor complex together with the beta (IL2RB) and gamma (common gamma chain, IL2RG) subunits. While IL2RA itself does not possess intrinsic signaling capability, its expression dramatically increases the affinity of the receptor complex for interleukin-2, enabling efficient downstream signaling through JAK-STAT pathways. This mechanism is essential for clonal expansion of activated T cells and maintenance of immune responses. Use of an IL2RA antibody enables investigation of IL-2 receptor assembly, signaling dynamics, and cytokine responsiveness.<br><br>CD25 expression is a defining feature of regulatory T cells, which constitutively express high levels of Interleukin-2 receptor subunit alpha to support immune tolerance and suppression of excessive immune activation. Because of this characteristic expression pattern, IL2RA antibody reagents are widely applied as markers for regulatory T cell identification and functional studies. CD25 is also transiently expressed on activated conventional T cells, B cells, and certain innate immune cell populations, reflecting its broader role in immune activation.<br><br>Interleukin-2 receptor subunit alpha has significant relevance in autoimmune disease, transplantation, and cancer immunology. Dysregulated IL2RA expression or IL-2 signaling contributes to autoimmune pathogenesis, while therapeutic targeting of CD25 has been explored for immune modulation in transplantation and immune-mediated disease. In oncology research, IL2RA expression on activated lymphocytes and tumor-infiltrating immune cells provides insight into immune status within the tumor microenvironment. An IL2RA antibody therefore supports studies of immune dysregulation, tolerance mechanisms, and therapeutic immune modulation.<br><br>Structurally, Interleukin-2 receptor subunit alpha is a type I transmembrane glycoprotein with an extracellular cytokine-binding domain and a short cytoplasmic tail. Its expression is tightly regulated at the transcriptional and post-translational levels in response to immune stimuli. Because IL2RA expression reflects immune activation state and regulatory function, antibody-based detection of this protein is central to studies of adaptive immunity and immune homeostasis.<br><br>Clone rIL2RA/12624 is designed to recognize Interleukin-2 receptor subunit alpha and supports detection of IL2RA expression in research applications. NSJ Bioreagents offers this IL2RA antibody to support investigations into T cell biology, regulatory T cell function, cytokine signaling, and immune regulation.

Specifications